α1-Antitrypsin deficiency associated with increased risk of heart failure
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 587 KB, PDF-dokument
Methods: In a nationwide nested study of 2209 patients with α1-antitrypsin deficiency and 21 869 controls without α1-antitrypsin deficiency matched on age, sex and municipality, we recorded admissions and deaths due to heart failure during a median follow-up of 62 years. We also studied a population-based cohort of another 102 481 individuals from the Copenhagen General Population Study including 187 patients from the Danish α1-Antitrypsin Deficiency Registry, all with genetically confirmed α1-antitrypsin deficiency.
Results: Individuals with versus without α1-antitrypsin deficiency had increased risk of heart failure hospitalisation in the nationwide cohort (adjusted hazard ratio 2.64, 95% CI 2.25–3.10) and in the population-based cohort (1.77, 95% CI 1.14–2.74). Nationwide, these hazard ratios were highest in those without myocardial infarction (3.24, 95% CI 2.70–3.90), without aortic valve stenosis (2.80, 95% CI 2.38–3.29), without hypertension (3.44, 95% CI 2.81–4.22), without atrial fibrillation (3.33, 95% CI 2.75–4.04) and without any of these four diseases (6.00, 95% CI 4.60–7.82). Hazard ratios for heart failure-specific mortality in individuals with versus without α1-antitrypsin deficiency were 2.28 (95% CI 1.57–3.32) in the nationwide cohort and 3.35 (95% CI 1.04–10.74) in the population-based cohort.
Conclusion: Individuals with α1-antitrypsin deficiency have increased risk of heart failure hospitalisation and heart failure-specific mortality in the Danish population.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 00319-2023 |
Tidsskrift | ERJ Open Research |
Vol/bind | 9 |
Udgave nummer | 5 |
Antal sider | 10 |
ISSN | 2312-0541 |
DOI | |
Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
Support statement: This study was supported by the Alpha-1 Foundation, Coral Gables, FL, USA (grant number 612336); Novo Nordisk Foundation, Hellerup, Denmark (NNF19OC0058811); and Region Zealand Research Foundation, Sorø, Denmark (R19A341B233). The sponsors did not participate in the design and conduct of the study; collection, management, analysis or interpretation of the data; or in preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication. Funding information for this article has been deposited with the Crossref Funder Registry.
Publisher Copyright:
© The authors 2023.
ID: 387831708